Understanding the immune microenvironment of ovarian cancer
-
By
-
Meifeng Shen
-
Shuni Zhang
-
Yijun Zhu
-
Qiaoli He
-
Weiming Chen
-
June 10, 2026
-
Clinical Scorecard: Exploring the Immune Landscape in Ovarian Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Ovarian Cancer |
| Key Mechanisms | Immune checkpoint inhibitors (ICIs) face challenges due to CD8+- T cell exhaustion and a heterogeneous tumor immune microenvironment (TME). |
| Target Population | Patients with ovarian cancer. |
| Care Setting | Oncology and immunotherapy clinics. |
Key Highlights
- Single-cell RNA sequencing (scRNA-seq) reveals rare immune subsets and dynamic intercellular signaling in ovarian cancer.
- Terminally exhausted T cells evolve from GZMK+- progenitor populations.
- Ascitic fluid acts as an immunomodulatory reservoir affecting intratumoral immune dynamics.
- Myeloid–lymphoid crosstalk sustains localized immunosuppression and drives therapeutic resistance.
- High-resolution molecular insights guide the design of novel combinatorial regimens and adoptive cellular therapies.
Guideline-Based Recommendations
Diagnosis
- Characterization of the tumor immune microenvironment is essential for understanding therapeutic resistance.
Management
- Utilization of single-cell technologies to refine immunotherapeutic strategies.
Monitoring & Follow-up
- Assessment of CD8+- tumor-infiltrating lymphocytes (TILs) and their functional states.
Risks
- Prolonged exposure to the TME can lead to T cell exhaustion and loss of antitumor activity.
Patient & Prescribing Data
Patients diagnosed with ovarian cancer.
High levels of CD8+- TILs are associated with better prognosis, but their exhaustion can limit treatment efficacy.
Clinical Best Practices
- Employ single-cell sequencing to map immune cell heterogeneity in ovarian cancer.
- Monitor T cell functional states to predict ICI responsiveness.
- Consider the role of myeloid cells in the TME when designing treatment plans.
Related Resources & Content
